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Persistent left ventricular (LV) systolic dysfunction in patients with acute lymphocytic myo-
carditis (LM) is widely unexplored.
Objectives
To assess the frequency and predictors of persistent LV dysfunction in patients with LM and
reduced LVEF at admission.
Methods and results
We retrospectively evaluated 89 consecutive patients with histologically-proven acute myo-
carditis enrolled at three Italian referral hospitals. A subgroup of 48 patients with LM, base-
line systolic impairment and an available echocardiographic assessment at 12 months (6–
18) from discharge constituted the study population. The primary study end-point was
persistent LV dysfunction, defined as LVEF <50% at 1-year, and was observed in 27/48
patients (56.3%). Higher LV end-diastolic diameter at admission (odds ratio [OR] 1.22, 95%
confidence interval [CI] 1.04–1.43, p = 0.002), non-fulminant presentation (OR 8.46, 95% CI
1.28–55.75, p = 0.013) and presence of a poor lymphocytic infiltrate (OR 12.40, 95% CI
1.23–124.97, p = 0.010) emerged as independent predictors of persistent LV dysfunction at
multivariate analysis (area under the curve 0.91, 95% CI 0.82–0.99). Pre-discharge LVEF
was lower in patients with persistent LV dysfunction compared to the others (32%±8 vs.
53%±8, p <0.001), and this single variable showed the best accuracy in predicting the study
end-point (area under the curve 0.95, 95% CI 0.89–1.00).
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Conclusions
More than half of patients presenting with acute LM and LVEF <50% who survive the acute
phase show persistent LV dysfunction after 1-year from hospital discharge. Features of sub-
acute inflammatory process and of established myocardial damage at initial hospitalization
emerged as predictors of this end-point.
Introduction
Acute lymphocytic myocarditis (LM) presenting with left ventricular (LV) systolic dysfunction
represents a challenge in terms of diagnosis, management and prognostication [1–5]. Previous
studies showed that LV systolic dysfunction predicts poor in-hospital and long-term prognosis
in histologically-proven acute myocarditis [1, 2, 6] Moreover, patients with acute LM with
fulminant presentation, characterized by hemodynamic instability [7], have a worse in-hospi-
tal prognosis and are more prone to exhibit LV systolic dysfunction during follow-up with
respect to those with non-fulminant presentation [1, 8]. However, the natural history of the
specific subgroup of patients presenting with acute LM and LV systolic dysfunction is widely
unknown, particularly regarding the frequency and the early predictors of persistent LV dys-
function in the long term. These issues are relevant for defining tailored follow-up and therapy
in these high-risk patients. The aims of this study were: 1) to assess the proportion of patients
that will show persistently reduced LV ejection fraction (LVEF) at 1 year among those with
histologically-proven acute LM and impaired LV systolic function ad admission, and 2) to
identify early predictors of persistent LV systolic dysfunction.
Methods
Study population
We retrospectively analyzed all the patients with histologically proven acute myocarditis con-
secutively admitted at 3 Italian referral Centers for cardiomyopathies (Cardiovascular Depart-
ment of Trieste, De Gasperis Cardio Center, Niguarda Hospital of Milan and San Matteo
Hospital of Pavia) from 2000 to 2016. For the purpose of this study, the following inclusion cri-
teria were applied: 1) duration of heart failure (HF) symptoms�30 days; 2) impaired LV func-
tion (echocardiographic LV ejection fraction, LVEF, <50% at presentation; 3) histology and
immunohistochemistry findings consistent with LM at endomyocardial biopsy, according to
international criteria [9]; 4) available clinical and echocardiographic assessment within 12 (6–
18) months. Among 89 consecutively enrolled patients with biopsy-proven acute myocarditis
(46 from the Trieste Cardiovascular Department, 38 from the De Gasperis Cardio Center,
Niguarda Hospital, Milan, 5 from the Cardiovascular Department, Policlinico San Matteo,
Pavia), 57 (64.0%) patients were classified as LM and had LV systolic dysfunction. Four
patients (5.2%) with fulminant myocarditis died or underwent heart transplant during the ini-
tial hospitalization. Five (8.7%) patients surviving more than 1 year after hospital discharge
had no available follow-up echocardiographic information. Thus, the study population con-
sisted of the remaining 48 patients (Fig 1). The clinical and echocardiographic evaluation for
the assessment of possible persistent LV systolic dysfunction was performed at a median time
of 10 months (interquartile range, 8 to 12).
The study was approved by the Ethic Committees of Trieste, Milan and Pavia Hospitals.
The study complied with the declaration of Helsinki.
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Patients management
All the patients underwent a thorough invasive and non-invasive assessment at index hospital-
ization. In all the patients surviving the acute phase, clinical follow-up within 12 (6–18)
months from index hospitalization was scheduled, including clinical evaluation, laboratory
testing, and echocardiographic assessment.
Endomyocardial biopsy
Endomyocardial biopsy (EMB) was performed from either the left or the right ventricle
according to the Center experience or single case evaluation. The mean number of histological
samples per patient was 4 (range 1–6) [10, 11]. Samples for histopathological analysis were
fixed in 10% buffered formalin, paraffin embedded, sectioned on multiple levels at 2 μm, and
stained with Hematoxylin-Eosin (HE), Azan Mallory trichrome and Weigert van Gieson
stains. Congo Red staining for amyloid, Perl’s staining for iron deposits and colloidal iron
staining for amorphous substance in the young connective tissue was performed if necessary.
The following antigens were tested if necessary using specific antibodies for identification of
myocardial inflammation and for the identification, localization, and characterization of
mononuclear cell infiltrates: human leukocyte antigen (HLA)-DR-α to assess HLA class II
expression in antigen-presenting immune cells; CD3 for T cells; CD4 for helper T-cells; CD8
Fig 1. Flow diagram describing the selection of the study population. EMB, Endomyocardial biopsy.
https://doi.org/10.1371/journal.pone.0214616.g001
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for suppressor T-cells; CD68 KP1 and CD 163 for activated macrophages. In all cases a signifi-
cant lymphocytic infiltrate was present [12] and was associated with a positive immunohis-
tochemistry analysis. The grading of the myocardial inflammatory infiltrates was performed
blindly on a scale of poor, moderate and plentiful. ‘Poor’ represented focal distribution of myo-
cardial lesions with a diameter< 100 μm, ‘plentiful’ indicated the presence of multiple lesions
over the entire sample, while ‘moderate’ denoted intermediate severity. The most frequently
scored severity of cellular infiltration and myocardial necrosis in each stain was considered
representative of myocardial pathology [13]. Samples from patients without an acute fulmi-
nant condition were evaluated for the presence of the genome of cardiotropic viruses (Parvovi-
rus B19, Adenovirus, Enterovirus, Ebstein-Barr Virus, Herpes Simplex Virus 1, Herpes
Simplex Virus 2) by Real Time Polymerase Chain Reaction (PCR) using specific primers and
probes. In case of virus-positive EMB, blood samples were also tested for the same virus. In ful-
minant forms, viral PCR were not routinely performed. All specimens have been carefully eval-
uated by the resident pathologist.
Therapy
When clinical condition was sufficiently stable, patients received recommended HF medical
treatment as indicated by current guidelines. Patients with fulminant forms, defined by the
need for inotropes or vasopressors and/or mechanical circulatory support during the acute
phase [7, 8], were mostly treated with intravenous corticosteroids early after histological con-
firmation as previously reported [8]. In the other patients, immunosuppressive therapy was
administrated in the presence of 1) myocardial immune activation at immunohistochemistry
analysis, 2) persistent LV dysfunction under standard treatment[5], and 3) absence of viral
genome in myocardial cells by Real Time Polymerase Chain Reaction. Immunosuppressive
therapy consisted of prednisone (50 mg/m2/day with progressive downscaling) and azathio-
prine (75 mg/m2/day) for a 6-month period [1].
Echocardiographic assessment
Echocardiographic assessment consisted in comprehensive M-mode, 2-dimensional and
Doppler studies. Systolic and diastolic ventricular function and valve regurgitations were
defined according to international guidelines [14]. In particular, LVEF was calculated from
2-dimensional apical 4 and 2 chambers approach using the biplane method of discs (modified
Simpson’s rule). LVEF was systematically measured at admission, prior to discharge and at fol-
low-up in all patients included.
Study design and end-points
The primary study end-point was the persistence of a LVEF <50% at follow-up [15]. Second-
ary end-point was the long-term survival-free from cardiovascular death or heart transplant
(HTx).
Follow-up information were obtained through phone calls with patients, their relatives, or
general practitioner or by consulting the office of national statistics. The end of follow-up was
considered as June 30, 2017 (last check date of status for alive patients) or the date of death or
HTx.
Statistical analysis
Summary statistics of clinical and laboratory variables were expressed as mean and standard
deviation, median and interquartile range or counts and percentage, as appropriate (Shapiro-
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Wilk test was used to test for normal distribution of continuous variables). Comparisons
between groups were made by the ANOVA test on continuous variables, using the Brown-For-
sythe statistic when the assumption of equal variances did not hold, or the non-parametric
Mann-Whitney test when necessary. The Chi-square or Fisher’s exact test were calculated for
discrete variables. Uni- and multi-variable logistic regression analyses were estimated to deter-
mine the most predictive combination of independent factors associated with the primary
end-point, by means of a full-model strategy applied each time starting from a different subset
of at most three parameters, due to the low event rate. For each combination of parameters,
the predictive accuracy of the corresponding vector of estimated probabilities of event was
evaluated by means of a receiver operating characteristic (ROC) curve. Since the limited num-
ber of events, the De Long test between areas under the curves (AUCs) had a limited power,
and for this reason the model with the absolute highest accuracy was retained. This final
model was internally validated with a bootstrap-based procedure, in order to account for the
optimism in the AUC estimate [16]. To explore the secondary end-point, i.e. the long-term
survival outcome, Kaplan-Meier survival curves were estimated (starting from the date of re-
evaluation) and the Log-rank test was performed.
Linear association between variables was analysed using Pearson’s correlation coefficient
for normally distributed variables and Spearman’s correlation coefficient for not normally dis-
tributed variables and significance of both coefficients was reported. The IBM-SPSS version 19




Baseline characteristics of the studied cohort (n = 48) are summarized in Table 1 (first col-
umn). Mean age was 38±16 years, and 52% were males. The median time between the onset of
symptoms and hospitalization 11 days (interquartile range, 5 to 26). Most of the patients
(n = 40, 83%) presented a flu-like syndrome before the onset of HF symptoms, but only 24
(50%) showed an increased C-reactive protein at admission. The mean LVEF was 26±9% and
the mean LV end-diastolic diameter [EDD] was 57±9 mm. PCR analysis was positive in 8
(24%) out of 33 tested patients, in all cases for Parvovirus B19. Immunosuppressive therapy
was administrated in 73% of patients.
Baseline predictors of persistent LVEF<50% at follow-up. After 10 months (interquar-
tile range, 8 to 12) of follow up, 27 patients (56%) showed a persistent LV systolic dysfunction.
One of these patients underwent HTx for refractory HF at 7 months from the diagnosis (this
patient was included in the main analysis since his LVEF was severely impaired at last available
echocardiographic evaluation of the native heart). At baseline, signs and symptoms of HF were
less severe (lower heart rate, higher systolic blood pressure, lower rate of NYHA IV class,
lower frequency of fulminant form) in patients with persistent LV systolic dysfunction at fol-
low up compared to the others. Moreover, patients with persistent LV dysfunction had a lon-
ger median duration of symptoms at admission (20 vs. 5 days, p<0.001) and, consistently,
presented with a larger LV size, showed more frequently a poor (rather than plentiful) lympho-
cytic infiltrate at EMB, and a lower LVEF at discharge in comparison with patients without
persistent LV dysfunction. Finally, they were younger and more frequently presented signs of
acute inflammation (higher CRP values and pericardial effusion, Table 1, 2nd and 3rd columns;
Fig 2). The two groups did not differ regarding the use of immunosuppressive therapy, ACE
inhibitors and aldosterone receptor antagonists. Patients with the recovery of LVEF were less
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treated with beta-blockers with respect to the patients with persistent LV dysfunction (62 vs.
93% respectively, p = 0.012).
Table 2 shows the baseline predictors of persistent LV systolic dysfunction at univariable
(left panel) and multivariable (right panel) analyses. The independent predictors of persistent
LV systolic dysfunction were: higher baseline LVEDD [Odds ratio (OR) 1.22, 95% confidence
interval (CI) 1.04–1.43, p = 0.002], non-fulminant presentation [OR 8.46, 95% CI 1.28–55.75,
p = 0.013], and a poor lymphocytic infiltrate [OR 12.40, 95% CI 1.23–124.97, p = 0.010]. ROC
analysis confirmed the highest accuracy of the model based on these variables compared to
the other possible models (area under the curve [AUC] 0.91, 95% CI 0.82–0.99, Fig 3, and S1
Table). Internal validation of this model showed a maximum error in predicted probabilities
of 0.08, and a bias-corrected AUC of 0.898.
LVEF at discharge and persistent LV dysfunction at follow-up. LVEF measured at pre-
discharge echocardiogram was significantly lower in patients that later showed persistent LV
Table 1. Baseline characteristics of study population divided on the basis of persistent left ventricular (LV) systolic dysfunction.
Study population Persistent LV dysfunction at follow-up Normal LV function at follow-up p
(N = 48) (N = 27, 56%) (N = 21, 44%)
Age (years) 38±16 43±14 32±15 0.03
Age <15 (%) 2 (4) 1 (4) 1 (5) 0.856
Male gender, n (%) 25 (52) 14 (52) 11 (52) 0.601
Duration of symptoms (days) 11 (5–26) 20 (14–28) 5 (3–6) <0.001
Admission Heart Rate (bpm) 95±34 81±25 114±36 0.001
Admission SBP (mmHg) 103±21 110±16 87±23 0.002
NYHA Class
II 17 (35) 11 (41) 7 (33) 0.880
III 14 (29) 12 (44) 2 (10) 0.008
IV 16 (33) 4 (15) 12 (60) 0.001
Fulminant forms, n (%) 23 (48) 6 (22) 17 (81) <0.001
Flu-like symptoms, n (%) 40 (83) 20 (74) 20 (95) 0.087
Increased CRP, n (%) 24 (50) 8 (30) 16 (76) <0.001
Atrial Fibrillation, n (%) 5 (10) 1 (4) 4 (19) 0.09
LBBB, n (%) 3 (6) 1 (4) 2 (10) 0.693
1st, 2nd, 3rd AV Blocks, n (%) 7 (15) 4 (15) 3 (14) 0.623
LVEDD (mm) 57±9 60±6 51±10 <0.001
Baseline LVEF (%) 26±9 28±7 24±11 0.211
LVEF at discharge (%) 42±13 32±8 53±8 <0.001
Pericardial effusion, n (%) 13 (27) 4 (15) 9 (43) 0.039
Poor lymphocytic Infiltrate�, n (%) 15 (31) 13 (48) 2 (10) 0.008
Moderate-to severe fibrosis at EMB 16 (33) 10 (37) 6 (29) 0.550
Beta-blockers at discharge, n (%) 38 (79) 25 (93) 13 (62) 0.012
ACE-inhibitors-ARBs at discharge, n (%) 43 (90) 24 (89) 19 (90) 0.621
Aldosterone receptors antagonist at discharge, n (%) 18 (38) 12 (44) 6 (29) 0.205
Immunosuppressive therapy (%) 35 (73) 20 (74) 15 (71) 0.838
Values are expressed as mean±SD or median with interquartile range as appropriate, and as percentage.
ACE, angiotensin converting enzyme; ARBs, angiotensin receptor blockers; AV, atrioventricular; CRP, C-reactive protein; EMB: endomiocardial biopsy; LBBB, left
bundle branch block; LM: lymphocytic myocarditis; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, ejection
fraction; MR, mitral regurgitation; RFP, restrictive filling pattern; SBP, systolic blood pressure;
�vs. moderate to plentiful
https://doi.org/10.1371/journal.pone.0214616.t001
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dysfunction at 1-year follow-up compared to the others (32%±8 vs. 53%±8 respectively,
p<0.001). At discharge, LVEF was already> 50% in the majority of the patients that showed
normal LV systolic function at 1-year follow-up (17/21, 81%). On the contrary, only one out of
the 27 patients with persistent LV dysfunction at 1 year (3.7%) exhibited a normal LVEF of
55% at discharge, which deteriorated to 35% at 12 months.
LVEF measured at pre-discharge had a similar accuracy in predicting persistent LV dys-
function at follow up compared to the admission model (AUC 0.946 95% CI 0.882–1.00).
Survived fulminant forms
Twenty-three (48%) patients of our population had fulminant acute myocarditis survived after
the acute phase. They were treated with intravenous inotropes, plus mechanical support in 13
(57%) of the cases. Among them, 83% had at least a moderate lymphocytic infiltrate and the
majority of them (78%) received immunosuppressive treatment. Six out of the 23 fulminant
forms (26%) showed persistent LV dysfunction at follow up. Compared with patients with ful-
minant presentation who recovered, they had similar baseline LVEF (22%±3 vs. 22%±9,
p = 0.96) but a less frequent plentiful infiltrate at EMB (6 vs. 50%, p = 0.03) and a lower rate of
normalized LVEF at pre-discharge (0 vs. 65%, p<0.001). (S2 Table).
Fig 2. Histological images of three patients with acute LM presenting left ventricular dysfunction at admission. A-B) Fulminant
form with plentiful lymphocytic infiltrate and necrosis, he died during the acute phase (excluded from main analysis); C-D)
Fulminant form with plentiful lymphocytic infiltrate, he normalized systolic function during follow-up (included in the main
analysis); E-F) non-fulminant form with poor lymphocytic infiltrate, he will maintain LV dysfunction during follow-up (included in
the main analysis). LM: Lymphocytic Myocarditis; LV: Left Ventricular. A) HE showing diffuse inflammatory infiltrates and
myocardial necrosis. B)Immunohistochemistry showing diffuse CD8+ T cells infiltrates (in red). C) HE showing moderate
inflammatory infiltrates and mild myocardial necrosis. D) Immunohistochemistry showing diffuse HLA-DR+ cells (in red). E) HE
showing poor inflammatory infiltrates and myocardial necrosis. F) Immunohistochemistry showing mild HLA-DR+ cells (in
brown).
https://doi.org/10.1371/journal.pone.0214616.g002
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Long-term outcome
During a median follow-up of 48 (interquartile range 16–94) months, patients with persistent
LV dysfunction at follow-up showed a trend for higher rates of cardiac death or HTx com-
pared with patients showing normalized LVEF (p = 0.08, Fig 4). In the subgroup characterized
by recovery of LVEF during follow-up, there were 4 events (all occurred within the first 30
months of follow-up). Conversely, no events in the subgroup characterized by of LVEF during
follow-up.
Discussion
This study evaluates a cohort of patients with acute LM, presenting with HF symptoms of
recent onset (� 30 days) and LV dysfunction (mean LVEF at admission 26%). To the best of
our knowledge, this study is the first report on persistent LV systolic dysfunction in histologi-
cally proven lymphocytic myocarditis, and provides some important insights: 1) more than
half of the patients surviving the index hospitalization exhibited persistent LV systolic dysfunc-
tion, at discharge and during follow-up; 2) fulminant forms were characterized by a poor
outcome during hospitalization confirming recent studies [8] 3) increased LV size, poor lym-
phocytic infiltrate at EMB, non-fulminant presentation at admission, and lack of improvement
of LVEF at pre-discharge echocardiography predicted persistent LV systolic dysfunction at fol-
low-up in survivors.
Frequency and predictors of persistent LV dysfunction at follow up
Although LV systolic dysfunction is not very common in patients presenting with acute LM,
this setting constitutes a diagnostic and management challenge. [5] These patients often pres-
ent viral prodromal symptoms, but the causative agent remains frequently unknown despite
the use of real time PCR techniques aimed at detecting the specific viral agent in the myocar-
dium[17]. Our study shows that at 1-year follow-up, LVEF is<50% in more than half of
patients with LM presenting with LV systolic dysfunction at admission. Intriguingly, features
of a sub-acute inflammatory disease already present at the clinical onset, suggesting an evolv-
ing progressive cardiomyopathy process (i.e. poor lymphocytic infiltrate at EMB, dilated LV,
Table 2. Univariable and multivariable analyses for persistent LV systolic dysfunction.
Univariable Multivariable
OR 95% C.I. p OR 95% C.I. p
Agea 1.06 1.01–1.11 0.015
Heart Ratea 0.96 0.93–0.98 0.001
SBPa 1.10 1.020–1.192 0.014
Non-fulminant forms (if surviving to the acute phase) 14.87 3.60–61.39 <0.001 8.46 1.28–55.75 0.013
Poor Lymphocytic Infiltrate 9.45 1.77–50.47 0.009 12.4 1.23–124.97 0.010
Baseline LVEDDa 1.19 1.06–1.34 0.003 1.22 1.04–1.43 0.002
Baseline LVEDVa 1.02 1.00–1.04 0.018
Pericardial Effusion 0.18 0.04–0.80 0.024
Baseline increased CRP 0.089 0.02–0.39 0.001
SBP, systolic blood pressure; EF, ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; MR, mitral
regurgitation; RFP, restrictive filling pattern; TAPSE, tricuspid annular plane systolic excursion; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane
oxygenation; CRP, C-reactive protein; EMB, endomyocardial biopsy;
a. Odds ratio estimation is referred to every unit increase for continuous variables.
https://doi.org/10.1371/journal.pone.0214616.t002
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and non-fulminant presentation), appear to be related to persistent LV dysfunction at follow-
up. Despite a maximum of 30 days of symptoms as inclusion criterion of this study, it is possi-
ble that patients with persistent LV dysfunction had been evaluated and treated later along the
course of the inflammatory process in comparison with patients who fully recovered. In fact, a
younger age as well as an increased C-reactive protein and pericardial effusion at admission
were more frequent in patients who recovered compared with those who did not. While
Fig 3. Receiver operating curves analysis for baseline prediction model of persistent LV systolic dysfunction during follow-up. The model
including poor lymphocytic infiltrate + left ventricular end-diastolic diameter + non-fulminant myocarditis when surviving to the acute phase showed
the highest accuracy. Legend. AUC, area under the ROC curve; CI, confidence interval; LVEF: left ventricular ejection fraction;
https://doi.org/10.1371/journal.pone.0214616.g003
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inflammation tend to spontaneous resolution over time, patients that did not recover showed
only a poor inflammatory infiltrate as probably a relevant quota of damage already occurred
with lower probability of LVEF recovery despite the implementation of optimal therapeutic
strategies (including early supportive therapy, standard HF therapy, immunosuppression).
Finally, patients with persistent LV systolic dysfunction showed a trend of worse long-term
prognosis compared to patients that normalized LVEF. Interestingly, the overall event rate was
relatively low, and all the events occurred in the first 3 years after diagnosis confirming recent
reports on post-myocarditis dilated cardiomyopathy [18].
Fulminant forms
Fulminant forms comprised almost half of our cohort. It must be noted that more than 80% of
fulminant cases who survived presented at least moderate inflammatory infiltration and most
of them were treated with steroids. More than 75% of patients with fulminant myocarditis who
survived after the acute phase showed a normal LV systolic function already at the discharge.
This could explain the apparently paradoxical low percentage of beta-blockers in the group of
patients with LVEF recovery at follow-up evaluation. However, 26% of survived fulminant
myocarditis were characterized by persistent LV systolic dysfunction at 1 year. Notably, they
were characterized by a poor inflammation at EMB performed at index hospitalization. These
finding underscores the need of individualized long-term follow-up and therapy [8].
Clinical implications
This study considers one of the largest cohorts of biopsy-proven acute LM patients with LV
systolic dysfunction at presentation, and some clinical implications for patient management
Fig 4. Central illustration. Long-term D/HTx-free survival curves according to the persistent LV systolic dysfunction during
follow-up. The curves start from follow-up revaluation. Legend. LV: Left Ventricular; D/HTx: Death or Heart Transplantation.
https://doi.org/10.1371/journal.pone.0214616.g004
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and further studies may be derived: 1) early endomyocardial biopsy is highly recommended in
patients with clinically suspected myocarditis and newly diagnosed significant LV dysfunction:
these patients should be promptly referred to experienced centers for both diagnosis and treat-
ment, that may include advanced circulatory support and transplantation; 2) time course of
LV dysfunction must be followed and characterized during index hospitalization, since signifi-
cant improvement of LVEF may occur, and pre-discharge LVEF predicts long-term LV func-
tion; 3) fulminant myocarditis portends a high risk for early death or need for HTX, but full
recovery is possible, often persistent over time. This observation, together with the high rate of
persistent LV dysfunction and its association with dilated LV and smoldering inflammation at
EMB at admission -which may reflect delayed diagnosis- and some recent evidences [19], sug-
gest to consider a prospective study on early steroid therapy in patients with acute lymphocytic
myocarditis and severe LV dysfunction.
Limitations
This study suffers from the intrinsic methodological limitations of all observational retrospec-
tive studies. Moreover, the study population derives from tertiary referral centers and this con-
stitutes a selection bias. Our study considered a small number of patients and events and this
explain wide confidence intervals of the estimates, even if the boostrap-based internal valida-
tion of the regression model gave satisfactory results.
Troponin essays used in the enrolling Centers were different. As a consequence, it was not
possible to use the troponin values at diagnosis as included variable, despite it was generally
increased in the study patients.
Data derived from cardiac magnetic resonance (CMR) or laboratory data such as natri-
uretic peptides and troponin were available in a minority of our patients and therefore were
not considered. This limitation is due to the long enrollment period with patients enrolled
more than 10 years ago, when especially CMR use was not as widespread as today. The rele-
vance of late gadolinium enhancement detected at CMR can provide further hints to identify
patients at risk to maintain LV dysfunction at follow up evaluation as suggested by recent stud-
ies [6].
Given the retrospective and observational nature of the study and the differences in timing
of initiation, drug combination and doses, and duration of immunosuppressive therapy, no
inferences can be derived about the role of immunosuppression in acute myocarditis with LV
dysfunction.
Conclusions
Patients with acute lymphocytic myocarditis presenting with LV systolic dysfunction exhibit a
persistent LV impairment at 1-year in more than 50% of the cases.
Features suggestive of a poor inflammatory process associated with cardiac enlargement,
and lack of early recovery, emerged as potential useful tools for predicting persistent LV sys-
tolic dysfunction during follow-up.
Supporting information
S1 Table. Performance of the principal different multivariable model at admission.
(DOCX)
S2 Table. Patients with survived fulminant forms: Baseline characteristics of patients with
versus without persistent left ventricular systolic dysfunction.
(DOCX)
Persistent LV dysfunction after acute myocarditis
PLOS ONE | https://doi.org/10.1371/journal.pone.0214616 March 28, 2019 11 / 13
Author Contributions
Conceptualization: Marco Merlo, Enrico Ammirati.
Data curation: Marco Merlo, Enrico Ammirati, Piero Gentile, Jessica Artico.
Formal analysis: Marco Merlo, Enrico Ammirati, Piero Gentile, Jessica Artico, Giulia Barbati.
Supervision: Manlio Cipriani, Gianfranco Sinagra.
Writing – original draft: Marco Merlo, Enrico Ammirati, Piero Gentile, Jessica Artico.
Writing – review & editing: Marco Merlo, Antonio Cannatà, Gherardo Finocchiaro, Paola
Sormani, Marisa Varrenti, Andrea Perkan, Enrico Fabris, Aneta Aleksova, Rossana Bussani,
Duccio Petrella, Manlio Cipriani, Claudia Raineri, Maria Frigerio, Gianfranco Sinagra.
References
1. Anzini M, Merlo M, Sabbadini G, Barbati G, Finocchiaro G, Pinamonti B, et al. Long-term evolution and
prognostic stratification of biopsy-proven active myocarditis. Circulation. 2013; 128:2384–94. https://
doi.org/10.1161/CIRCULATIONAHA.113.003092 PMID: 24084750
2. Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, et al. A prospective study of biopsy-
proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Euro-
pean heart journal. 2007; 28:1326–33. https://doi.org/10.1093/eurheartj/ehm076 PMID: 17493945
3. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowl-
edge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the
European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European
heart journal. 2013; 34:2636–48, 48a–48d. https://doi.org/10.1093/eurheartj/eht210 PMID: 23824828
4. Cooper LT Jr. Myocarditis. The New England journal of medicine. 2009; 360:1526–38. https://doi.org/
10.1056/NEJMra0800028 PMID: 19357408
5. Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, et al. Myocarditis in Clinical
Practice. Mayo Clinic proceedings. 2016; 91:1256–66. https://doi.org/10.1016/j.mayocp.2016.05.013
PMID: 27489051
6. Grun S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term follow-up of biopsy-
proven viral myocarditis: predictors of mortality and incomplete recovery. Journal of the American Col-
lege of Cardiology. 2012; 59:1604–15. https://doi.org/10.1016/j.jacc.2012.01.007 PMID: 22365425
7. Ginsberg F, Parrillo JE. Fulminant myocarditis. Critical care clinics. 2013; 29:465–83. https://doi.org/10.
1016/j.ccc.2013.03.004 PMID: 23830649
8. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and Left Ventricular
Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation. 2017; 136:529–
45. https://doi.org/10.1161/CIRCULATIONAHA.117.026386 PMID: 28576783
9. Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 consensus statement on
endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society
for Cardiovascular Pathology. Cardiovasc Pathol. 2012; 21:245–74. https://doi.org/10.1016/j.carpath.
2011.10.001 PMID: 22137237
10. Escher F, Lassner D, Kuhl U, Gross U, Westermann D, Poller W, et al. Analysis of endomyocardial biop-
sies in suspected myocarditis—diagnostic value of left versus right ventricular biopsy. International jour-
nal of cardiology. 2014; 177:76–8. https://doi.org/10.1016/j.ijcard.2014.09.071 PMID: 25499345
11. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative eval-
uation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnos-
tic performance. Circulation. 2010; 122:900–9. https://doi.org/10.1161/CIRCULATIONAHA.109.
924167 PMID: 20713901
12. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr., et al. Myocarditis. A his-
topathologic definition and classification. The American journal of cardiovascular pathology. 1987; 1:3–
14. PMID: 3455232
13. Yuan Z, Shioji K, Kishimoto C. Immunohistological analyses of myocardial infiltrating cells in various ani-
mal models of myocarditis. Experimental and clinical cardiology. 2003; 8:13–6. PMID: 19644581
14. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for car-
diac chamber quantification by echocardiography in adults: an update from the American Society of
Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr.
2015; 28:1–39. https://doi.org/10.1016/j.echo.2014.10.003 PMID: 25559473
Persistent LV dysfunction after acute myocarditis
PLOS ONE | https://doi.org/10.1371/journal.pone.0214616 March 28, 2019 12 / 13
15. Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The Diagnosis and Evaluation of Dilated Cardio-
myopathy. Journal of the American College of Cardiology. 2016; 67:2996–3010. https://doi.org/10.
1016/j.jacc.2016.03.590 PMID: 27339497
16. Harrell F. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and
Survival Analysis2007.
17. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. European heart journal. 2008; 29:2073–82.
https://doi.org/10.1093/eurheartj/ehn296 PMID: 18617482
18. Merlo M, Anzini M, Bussani R, Artico J, Barbati G, Stolfo D, et al. Characterization and Long-Term Prog-
nosis of Postmyocarditic Dilated Cardiomyopathy Compared With Idiopathic Dilated Cardiomyopathy.
The American journal of cardiology. 2016; 118:895–900. https://doi.org/10.1016/j.amjcard.2016.05.063
PMID: 27453513
19. Merken J, Hazebroek M, Van Paassen P, Verdonschot J, Van Empel V, Knackstedt C, et al. Immuno-
suppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative
Nonfulminant Inflammatory Cardiomyopathy. Circulation Heart failure. 2018; 11:e004228. https://doi.
org/10.1161/CIRCHEARTFAILURE.117.004228 PMID: 29449368
Persistent LV dysfunction after acute myocarditis
PLOS ONE | https://doi.org/10.1371/journal.pone.0214616 March 28, 2019 13 / 13
